{"doi":"10.1093/cercor/bhaa326","title":"NECAB1 and NECAB2 are Prevalent Calcium-Binding Proteins of CB1/CCK-Positive GABAergic Interneurons","abstract":"The molecular repertoire of the \"Ca2+-signaling toolkit\" supports the specific kinetic requirements of Ca2+-dependent processes in different neuronal types. A well-known example is the unique expression pattern of calcium-binding proteins, such as parvalbumin, calbindin, and calretinin. These cytosolic Ca2+-buffers control presynaptic and somatodendritic processes in a cell-type-specific manner and have been used as neurochemical markers of GABAergic interneuron types for decades. Surprisingly, to date no typifying calcium-binding proteins have been found in CB1 cannabinoid receptor/cholecystokinin (CB1/CCK)-positive interneurons that represent a large population of GABAergic cells in cortical circuits. Because CB1/CCK-positive interneurons display disparate presynaptic and somatodendritic Ca2+-transients compared with other interneurons, we tested the hypothesis that they express alternative calcium-binding proteins. By in silico data mining in mouse single-cell RNA-seq databases, we identified high expression of Necab1 and Necab2 genes encoding N-terminal EF-hand calcium-binding proteins 1 and 2, respectively, in CB1/CCK-positive interneurons. Fluorescent in situ hybridization and immunostaining revealed cell-type-specific distribution of NECAB1 and NECAB2 throughout the isocortex, hippocampal formation, and basolateral amygdala complex. Combination of patch-clamp electrophysiology, confocal, and STORM super-resolution microscopy uncovered subcellular nanoscale differences indicating functional division of labor between the two calcium-binding proteins. These findings highlight NECAB1 and NECAB2 as predominant calcium-binding proteins in CB1/CCK-positive interneurons.","journal":"Cerebral Cortex","year":2020,"id":95034,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9504,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":472878,"name":"Krisztina Kelemen","orcid":"0000-0002-6113-3419","position":1,"is_corresponding":false},{"id":474071,"name":"Judit R Glavinics","orcid":null,"position":2,"is_corresponding":false},{"id":472879,"name":"Zsófia I. László","orcid":"0000-0001-5317-1207","position":3,"is_corresponding":false},{"id":472880,"name":"Benjámin Barti","orcid":"0000-0002-1669-2246","position":4,"is_corresponding":false},{"id":472881,"name":"Kata Kenesei","orcid":"0000-0001-5711-885X","position":5,"is_corresponding":false},{"id":472882,"name":"Máté Kisfali","orcid":"0000-0001-8932-3559","position":6,"is_corresponding":false},{"id":472883,"name":"István Katona","orcid":"0000-0003-2808-3330","position":7,"is_corresponding":false},{"id":472877,"name":"Vivien Miczán","orcid":"0000-0003-0457-4899","position":0,"is_corresponding":true}],"reference_count":157,"raw_metadata":null,"created_at":"2026-07-18T22:33:30.364261Z","pmid":"33230531","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}